Diapin Therapeutics is developing novel therapeutics to treat patients with type 2 diabetes. Our major effort is to develop an orally active 3 amino acid peptide to lower blood glucose. This peptide interacts with a G-protein-coupled receptor not previously implicated in glucose control. Our second project is to develop a stable conjugate of the active metabolite of Plavix (clopidogrel) to overcome clopidogrel resistance in diabetes patients.